
ORMP Valuation
Oramed Pharmaceuticals Inc
- Overview
- Forecast
- Valuation
- Earnings
ORMP Relative Valuation
ORMP's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ORMP is overvalued; if below, it's undervalued.
Historical Valuation
Oramed Pharmaceuticals Inc (ORMP) is now in the Fair zone, suggesting that its current forward PS ratio of 43.30 is considered Fairly compared with the five-year average of -10.93. The fair price of Oramed Pharmaceuticals Inc (ORMP) is between 0.56 to 5.89 according to relative valuation methord.
Relative Value
Fair Zone
0.56-5.89
Current Price:2.08
Fair
-6.12
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Oramed Pharmaceuticals Inc. (ORMP) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.47. The thresholds are as follows: Strongly Undervalued below -8.77, Undervalued between -8.77 and -5.12, Fairly Valued between 2.19 and -5.12, Overvalued between 2.19 and 5.84, and Strongly Overvalued above 5.84. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.58
EV/EBIT
Oramed Pharmaceuticals Inc. (ORMP) has a current EV/EBIT of 0.58. The 5-year average EV/EBIT is -2.56. The thresholds are as follows: Strongly Undervalued below -16.63, Undervalued between -16.63 and -9.59, Fairly Valued between 4.47 and -9.59, Overvalued between 4.47 and 11.50, and Strongly Overvalued above 11.50. The current Forward EV/EBIT of 0.58 falls within the Historic Trend Line -Fairly Valued range.
43.30
PS
Oramed Pharmaceuticals Inc. (ORMP) has a current PS of 43.30. The 5-year average PS is 81.87. The thresholds are as follows: Strongly Undervalued below -56.86, Undervalued between -56.86 and 12.50, Fairly Valued between 151.24 and 12.50, Overvalued between 151.24 and 220.60, and Strongly Overvalued above 220.60. The current Forward PS of 43.30 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/OCF
Oramed Pharmaceuticals Inc. (ORMP) has a current P/OCF of 0.00. The 5-year average P/OCF is -5.75. The thresholds are as follows: Strongly Undervalued below -30.44, Undervalued between -30.44 and -18.09, Fairly Valued between 6.60 and -18.09, Overvalued between 6.60 and 18.95, and Strongly Overvalued above 18.95. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Oramed Pharmaceuticals Inc. (ORMP) has a current P/FCF of 0.00. The 5-year average P/FCF is -3.03. The thresholds are as follows: Strongly Undervalued below -18.58, Undervalued between -18.58 and -10.80, Fairly Valued between 4.74 and -10.80, Overvalued between 4.74 and 12.51, and Strongly Overvalued above 12.51. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Oramed Pharmaceuticals Inc (ORMP) has a current Price-to-Book (P/B) ratio of 0.60. Compared to its 3-year average P/B ratio of 0.84 , the current P/B ratio is approximately -27.88% higher. Relative to its 5-year average P/B ratio of 1.96, the current P/B ratio is about -69.27% higher. Oramed Pharmaceuticals Inc (ORMP) has a Forward Free Cash Flow (FCF) yield of approximately -12.10%. Compared to its 3-year average FCF yield of -13.18%, the current FCF yield is approximately -8.22% lower. Relative to its 5-year average FCF yield of -12.14% , the current FCF yield is about -0.33% lower.
0.60
P/B
Median3y
0.84
Median5y
1.96
-12.10
FCF Yield
Median3y
-13.18
Median5y
-12.14
Competitors Valuation Multiple
The average P/S ratio for ORMP's competitors is 7.45, providing a benchmark for relative valuation. Oramed Pharmaceuticals Inc Corp (ORMP) exhibits a P/S ratio of 43.30, which is 481.32% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of ORMP increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of ORMP in the past 1 year is driven by Unknown.
People Also Watch

SHIM
Shimmick Corp
2.390
USD
+13.27%

CODA
Coda Octopus Group Inc
7.730
USD
+1.84%

PAVS
Paranovus Entertainment Technology Ltd
0.770
USD
+1.99%

ALOT
AstroNova Inc
11.270
USD
-1.23%

CTOR
Citius Oncology Inc
1.690
USD
-1.74%

ALXO
ALX Oncology Holdings Inc
0.644
USD
-1.68%

IROH
Iron Horse Acquisitions Corp
7.000
USD
0.00%

HSPO
Horizon Space Acquisition I Corp
12.190
USD
+1.16%

VOR
Vor Biopharma Inc
2.140
USD
+8.08%

FSHP
Flag Ship Acquisition Corp
10.510
USD
+0.10%
FAQ

Is Oramed Pharmaceuticals Inc (ORMP) currently overvalued or undervalued?
Oramed Pharmaceuticals Inc (ORMP) is now in the Fair zone, suggesting that its current forward PS ratio of 43.30 is considered Fairly compared with the five-year average of -10.93. The fair price of Oramed Pharmaceuticals Inc (ORMP) is between 0.56 to 5.89 according to relative valuation methord.

What is Oramed Pharmaceuticals Inc (ORMP) fair value?

How does ORMP's valuation metrics compare to the industry average?

What is the current P/B ratio for Oramed Pharmaceuticals Inc (ORMP) as of Aug 18 2025?

What is the current FCF Yield for Oramed Pharmaceuticals Inc (ORMP) as of Aug 18 2025?

What is the current Forward P/E ratio for Oramed Pharmaceuticals Inc (ORMP) as of Aug 18 2025?
